FirstImpact Report:
ENHANCE trial results – physicans' evolving reactions
Report Format: PDF via email
Price: $4,395 USD*
*Price for a Single License/User.
Please contact us for a Department
License/Multiple Users.
How are prescribing intentions for Vytorin evolving?
On January 14, 2008, Merck/Schering-Plough released preliminary ENHANCE trial results which found that Vytorin (Zetia/Zocor combination) was not better than Zocor in plaque reduction. Since then conflicting opinions have emerged regarding the impact of this news on physicians' prescribing intentions.
The Vytorin FirstImpact Report will tell you what physicians really think of the trial results and how these continue to impact treatment decisions for patients.
FirstImpact can help you understand the continued impact of the Vytorin news!
The FirstImpact Report for Vytorin gives you:
- Reactions directly from physicians – we surveyed 220 general practitioners and cardiologists about the course of action they will adopt as a result of the news surrounding the ENHANCE trial results.
- Fast feedback – physicians were surveyed 2 days and then 2 weeks after the announcement of the ENHANCE trial results, and a FirstImpact Report containing results from these 2 studies is now available.
- Reliable insights – since our report analysis is based on physicians’ own responses, it allows you to confidently rely on market feedback rather than making due with speculation about market changes.
What questions will the Vytorin FirstImpact Report answer for you?
The FirstImpact Report provides you graphical analysis and report commentary to answer the business critical questions detailed in this table of contents:
REPORT OVERVIEW
- Introduction
- Methodology overview
- Summary of key findings
PHYSICIANS REACTIONS TO THE VYTORIN NEWS
- What are physicians’ current opinions of the news about Vytorin?
- Is the news influencing perceptions of Merck, Schering-Plough and others?
- Do physicians feel the ENHANCE trial results apply to other patient types?
- What impact do physicians feel the ENHANCE trial result will have on their prescribing decisions?
INTENTIONS FOR PATIENTS CURRENTLY TREATED WITH VYTORIN
- What course of action do physicians intend to take for patients currently treated with Vytorin?
- To what therapies will patients be switched?
- Are patients already contacting physicians about the Vytorin news?
- How will physicians react to patient requests to be taken off Vytorin?
IMPACT ON SHARE-OF-PATIENTS STARTING A NEW TREATMENT
HELPING PHYSICIANS BETTER UNDERSTAND THE VYTORIN NEWS
